How Section 280E has cost cannabis companies billions — and why rescheduling would change everything

Section 280E of the Internal Revenue Code is a single sentence, written in 1982, that has cost the legal cannabis industry billions of dollars. If marijuana is rescheduled to Schedule III, that sentence would no longer apply — and the financial impact would reshape the industry overnight.

What 280E says

The provision is brutally simple: "No deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of schedule I and schedule II of the Controlled Substances Act) which is prohibited by Federal law."

In plain language: if your business traffics in Schedule I or Schedule II substances, you cannot deduct your business expenses from your federal taxes.

What this means in practice

Every legal business in America deducts ordinary and necessary business expenses — rent, payroll, utilities, marketing, insurance, equipment. These deductions are not a tax break; they're the basic mechanism by which businesses are taxed on their profits rather than their revenue.

Cannabis companies cannot take these deductions. The result is that marijuana businesses pay effective federal tax rates of 60-80% — roughly three to four times the rate paid by comparable businesses in other industries.

A dispensary earning $5 million in revenue with $4 million in expenses and $1 million in actual profit doesn't pay taxes on the $1 million. It pays taxes on something much closer to the full $5 million, because those $4 million in expenses are not deductible.

The cumulative cost

Industry analysts estimate that 280E has extracted between $15 billion and $20 billion in excess taxes from legal cannabis businesses since Colorado and Washington launched adult-use sales in 2014. For individual companies, the numbers are staggering:

• Multi-state operators report 280E-related tax burdens of $50-100 million annually
• Smaller operators have been driven out of business entirely by the tax burden
• The provision is frequently cited as the single largest factor preventing cannabis companies from achieving sustained profitability

What Schedule III changes

Section 280E applies only to substances in Schedule I and Schedule II. If marijuana is moved to Schedule III — as HHS recommended in August 2023 and the DEA proposed in May 2024 — the provision would no longer apply.

Cannabis businesses would immediately be able to deduct the same expenses as any other legal business. The financial impact would be transformative:

• Effective tax rates would drop from 60-80% to the standard corporate rate of 21%
• Cash flow would improve dramatically, enabling investment in expansion and operations
• Profitability would become achievable for companies currently operating at a loss due to 280E
• Valuations of publicly traded cannabis companies would likely increase significantly

The catch

Rescheduling is not a certainty, and even if it occurs, the timeline remains unclear. The DEA's administrative hearing is suspended. Congressional opposition exists. And even after a final rule is published, legal challenges are expected.

Cannabis companies have been anticipating 280E relief for years. Until the rulemaking process reaches a conclusion, they continue paying tax rates that no other legal American industry faces.